Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 7/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30767969 | 1.00 | TEAD1 (0.61) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL25332868 | 1.00 | TEAD1 (0.61) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL30576458 | 1.00 | TEAD1 (0.61) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL27034710 | 1.00 | TEAD1 (0.61) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL30560824 | 0.89 | TEAD1 (0.52) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL25378751 | 0.89 | TEAD1 (0.52) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL31668903 | 0.89 | TEAD1 (0.52) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL25378746 | 0.89 | TEAD1 (0.52) | TEAD1MTNR1AMTNR1BGSK3BTGM2 | |
| SCHEMBL27034481 | 0.89 | TEAD1 (0.68) | TEAD1MTNR1AMTNR1BSLC6A2SLC6A4 | |
| SCHEMBL25331531 | 0.88 | MTNR1A (0.54) | TEAD1MTNR1AMTNR1BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | TEAD1 3/4885MTNR1A 1460/4885MTNR1B 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.